The Chronic Plaque Psoriasis Market encompasses a diverse array of treatment modalities, including topical corticosteroids, vitamin D analogues, phototherapy, systemic agents, and advanced biologic therapies. Biologics—monoclonal antibodies and fusion proteins—offer targeted inhibition of key immune mediators such as TNF-α, IL-17, and IL-23, delivering superior efficacy and safety over conventional treatments. Topical treatments remain essential for mild cases, whereas phototherapy bridges the gap between topical and systemic approaches. Systemic agents like methotrexate and cyclosporine continue to play a role in moderate to severe disease management, but their side-effect profiles spur demand for more selective biologics. The market’s growth is underpinned by rising disease prevalence, increased screening, and growing patient awareness of advanced therapies.

Favorable reimbursement policies and ongoing R&D investments further boost market opportunities. As Chronic Plaque Psoriasis Market players expand their portfolios through partnerships and licensing deals, the competitive landscape intensifies, driving down costs and broadening access. The integration of digital health solutions and teledermatology is enhancing patient adherence and monitoring, leading to improved outcomes.

The chronic plaque psoriasis market is estimated to be valued at USD 24.43 Bn in 2025 and is expected to reach USD 38.47 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Key Takeaways

Key players operating in the Chronic Plaque Psoriasis Market are Novartis, Eli Lilly and Company, AbbVie Inc., Johnson & Johnson (Janssen Biotech), and Amgen Inc.

These market companies lead in research funding and have secured substantial market share through blockbuster biologics like secukinumab, ixekizumab, and ustekinumab. Novartis leverages its strong global footprint to advance novel IL-23 inhibitors, while AbbVie’s Humira remains a top revenue generator despite biosimilar competition. Eli Lilly and Company is focusing on next-generation therapies and pipeline diversification, and Amgen Inc. continues strategic collaborations to bolster its psoriasis franchise. Janssen Biotech’s portfolio expansion and real-world evidence studies strengthen its competitive positioning. Collectively, these market players execute robust market growth strategies—mergers, acquisitions, and licensing agreements—to maintain leadership and accelerate innovation.

➢Get More Insights On: Chronic Plaque Psoriasis Market

➢Get this Report in Japanese Language:  慢性尋常性乾癬市場

➢Get this Report in Korean Language: 만성플라크건선시장

➢Read More Related Articles- Advances in Hemophilia Treatment in the United States Over the Past Few Decades